Menu
← Oncology Approval Tracker
FDA DECISION ·
Noxafil delayed-release tablets / injection
posaconazole · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Extends prophylaxis of invasive Aspergillus and Candida infections to high-risk pediatric patients age 2 and older, including specified transplant and hematologic malignancy populations. The delayed-release tablet use applies above 40 kg, while the injection expansion has no corresponding weight cutoff in the approval letter.
LAMPGEN ANALYSIS
Why it matters
These supplements extend existing oral and intravenous options to younger immunocompromised patients.
What research teams should watch
Record weight, route, transplant or neutropenia risk and the specific formulation in the prophylaxis plan.
PRIMARY RECORDS